The DOI matches its Crossref record; 889 of the 893 references it cites were found in a registry or an index, and 4 are not checked yet.
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Open accessAbstract
The individual reviewers' relationships with industry information is available in Appendix 2.This document was approved for publication by the governing bodies of the ASA and the AHA.It was reviewed for evidence-based integrity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with CKM stage 1 due to overweight and obesity are at increased risk for developing metabolic risk factors and CKD compared with those who have a normal weight without risk factors (CKM stage 0).5,6,41”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in the absence of these metabolic risk factors, excess weight is associated with increased cardiovascular risk, particularly for HF.6,42”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is a particular focus on preventing the development of excess and dysfunctional adipose tissue because the emergence of metabolic risk factors from youth and young adulthood into middle age is primarily related to weight gain with aging.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adults with overweight or obesity who have significant barriers to participating in multicomponent behavioral weight loss interventions, self-directed digital health solutions can be beneficial to promote weight loss for CKM syndrome risk reduction.5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among patients with CKM stage 1 to 3 and obesity without an adequate weight loss response to lifestyle modification, with or without the use of adjunctive obesity pharmacotherapies, MBS can be beneficial to facilitate weight loss and to mitigate CKM syndrome progression.1–8”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS has efficacy among individuals with a BMI ≥35 kg/m2 regardless of the presence of comorbidities and can be beneficial in patients with T2D with a threshold BMI of 30 kg/m2.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glycemia consistently improves with use of these agents, with some evidence for preventing progression to diabetes in those with insulin resistance.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS has efficacy among individuals with a BMI ≥35 kg/m2 regardless of the presence of comorbidities and can be beneficial in patients with T2D with a threshold BMI of 30 kg/m2.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Counseling on dietary or combined dietary and exercise modifications effectively facilitates weight loss in postpartum women with GDM.6,19–21”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RASi provide BP control and kidney and cardiovascular protection6 and are therefore preferred in patients with CKD and albuminuria.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials and meta-analyses of SGLT2i in patients with CKD and T2D or CKD and UACR ≥200 mg/g without T2D have shown a significant reduction in risks of losing kidney function, kidney failure, cardiovascular death, and HF hospitalization when compared with placebo.5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of subclinical atherosclerosis (eg, elevated CAC) is associated with an increased cardiovascular risk among those with CKM risk factors (eg, diabetes, CKD).5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A heart-healthy diet and regular physical activity remain the cornerstones of therapy in patients with T2D and ASCVD, with demonstrated benefits for CKM risk profiles.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, habitual physical activity, including activities that reduce sedentary time, aerobic physical activity, and resistance training, are associated with improvements in several CKM risk factors (HbA1c, waist circumference, fat percentage, BP) and mortality.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS is associated with a lower risk of incident major adverse liver outcomes and MACE in large cohort studies.6,24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a 60% increased risk of stroke recurrence.35”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Standard stroke care includes medical treatment, routine stroke therapy, and rehabilitative exercises, as outlined in the basic guidelines [35,36].”
From Smartphone-Based Speech Therapy for Poststroke Dysarthria: Pilot Randomized Controlled Trial Evaluating Efficacy and Feasibility (2024) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, current guidelines recommend short-term dual antiplatelet therapy after high-risk transient ischemic attack and minor stroke (198).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [198]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, owing to the chronicity of obesity and multiple compensatory changes in metabolism, hunger, and satiety promoting weight recidivism,6 frequent and long-term engagement and behavioral support for lifestyle modification are needed for optimal effectiveness.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, as per clinical guidelines, persistently elevated triglycerides are considered a risk enhancer for ASCVD.2,4–6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“CAC assessment improves prediction of ASCVD4,5 and selection of patients for treatment with aggressive ASCVD risk factor modification (ie, statin therapy).6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“CorCal (Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of CAC Screening, in Preventing Future MACE)6 randomized 601 primary prevention patients to CAC (n=302) or risk calculator guidance (n=299) for primary prevention; the CAC arm had a greater reclassification of risk compared with the group using a risk calculator.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Once obesity is established, multiple compensatory mechanisms impacting metabolism, hunger, and satiety are triggered in the setting of intentional weight loss, which commonly result in weight regain.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In EMPA-Kidney, the risk reduction for the primary outcome (a composite of progression of kidney disease or death from cardiovascular causes) with empagliflozin compared with placebo was larger among patients with higher UACR (UACR ≥30–300: HR, 0.91; 95% CI, 0.65–1.26 versus UACR ≥300: HR, 0.67; 95% CI, 0.58–0.78).6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the rate of eGFR decline after the initial decrease was slower in the empagliflozin group than in the placebo group in all key subgroups, including in the subgroup of patients with a UACR <30 mg/g.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Simulation studies suggest that combinations of CKM therapies may have additive benefits for heart and kidney protection.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the SELECT trial,6 17 604 participants with BMI ≥27 kg/m2 and established ASCVD (prior MI, stroke, or symptomatic PAD), and without T2D, end-stage kidney disease, or dialysis, were enrolled. The trial demonstrated a 20% reduction in risk of the composite primary endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke for those treated with semaglutide (2.4 mg) as compared with placebo”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A single-arm 15-week pragmatic weight management program (weekly consultations with exercise specialists, dietitians, and behavioral specialists), achieved a mean weight loss of 8.1 kg (−6.7%) for patients with obesity-related HFpEF.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among patients with HFrEF, RASi improves both HF outcomes and risk for worsening kidney disease in several clinical trials.1–8,28”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A directionally similar reduction in risk of the cardiovascular outcome (cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization for HF) was observed in a subgroup with CKD G4 in the FIDELITY meta-analysis of finerenone in diabetic patients, but this was nonsignificant and requires further investigation.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Metabolic and bariatric surgery causes remission of MASLD, even in advanced stages.6,24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hyperkalemia was more frequent in those with CKD G4 treated with finerenone.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Abdominal adiposity is one of the strongest VTE risk factors.3,5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“Accordingly, many guidelines now recommend the addition of GLP-1RAs to ongoing antihyperglycemic regimens to lower the risk of stroke in type 2 diabetes.”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
In the citing paper
“the American Heart Association/American Stroke Association guideline suggests GLP-1RAs as second-line to metformin regardless of baseline HbA1c in individuals with established atherosclerotic CVD to avoid further vascular events 7”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
In the citing paper
“In the same vein, the 2020 Canadian Stroke Best Practices update for secondary prevention of stroke, 8 2021 Spanish Society of Neurology consensus statement, 9 2021 American Heart Association/American Stroke Association Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack, 7 and the Diabetes, Cardiorenal, and Metabolic Diseases Multispecialty Task Force 55”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Albay, C. E. Q., Leyson, F. G. D., & Cheng, F. C. (2020) · BMC Neurology · doi:10.1186/s12883-020-01808-y · Cited by 22
Retracted(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,350
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Research works printed but not linked: 11
- 10.1148/radiol.10100804 · DOI
- 10.1001/jama.1988.03720070025028 · DOI
- 10.1161/JAHA.117.00785 · DOI
- Inzucchi, SE, Docherty, K, Kober, L, Kosiborod, MN, Martinez, F. Effect of dapagliflozin on the incidence of diabetes: a prespecified exploratory analysis from DAPA-HF. Paper presented at: American Diabetes Association 80th Scientific Sessions; 2020; virtual.
- 10.1161/JAHA.116.00472 · DOI
- 10.1056/NEJMoa1910355 · DOI
- 10.1136/bmj.324.7329.7 · DOI
- 10.1182/blood.V63.1.162.162 · DOI
- 10.1043/0003-9985(2002)126<0182:AFIAHI>2.0.CO;2 · DOI
- Ubogu, EE, Zaidat, OO. Vertebrobasilar dolichoectasia diagnosed by magnetic resonance angiography and risk of stroke and death: a cohort study. J Neurol Neurosurg Psychiatry. 2004;75:22–26.
- Lawrence, K, Keleher, T. Structural Racism. Paper presented at: Race and Public Policy Conference; November 11–13, 2004; Berkeley, CA.
Cited by
Sorted by citations
Items 401–500 of 1,000
Ballout, A. A., Libman, R., Schneider, J. R., Ayoub, M., WANG, J. J., Patsalides, A. T., & Katz, J. M. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106539 · Cited by 17
Große, G. M., Hüsing, A., Stang, A., Kuklik, N., Brinkmann, M., Nabavi, D. G., Sparenberg, P., Weißenborn, K., Gröschel, K., Royl, G., et al. (2023) · International Journal of Stroke · doi:10.1177/17474930231184366 · Cited by 17
Perera, K. S., Sharma, M., Eikelboom, J. W., Ng, K. K. H., Field, T. S., Buck, B. H., Hill, M. D., Stotts, G., Casaubon, L. K., Mandzia, J. L., et al. (2025) · Stroke · doi:10.1161/strokeaha.124.047715 · Cited by 15
Stroke: Epidemiology, Risk Factors, Signaling Pathways, and Clinical Management
Ren, H., Liu, Y., Zhao, M., Shen, H., Nie, S., Gao, X., & Huang, Y. (2025) · MedComm · doi:10.1002/mco2.70558 · Cited by 24
Pathomechanisms and Treatment Implications for Stroke in COVID-19: A Review of the Literature
Stamm, B. J., Huang, D. L., Royan, R., Lee, J. H., Marquez, J., & Desai, M. J. (2022) · Life · doi:10.3390/life12020207 · Cited by 16
Yang, M., Cheng, H., Wang, X., Ouyang, M., Shajahan, S., Carcel, C., Anderson, C. S., Kristoffersen, E. S., Lin, Y., Sandset, E. C., et al. (2022) · Brain and Behavior · doi:10.1002/brb3.2752 · Cited by 16
Biologically Informed Clot Histomics Are Predictive of Acute Ischemic Stroke Etiology
Patel, T. R., Santo, B. A., Jenkins, T. D., Waqas, M. S., Monteiro, A., Baig, A. A., Levy, E. I., Davies, J. M., Snyder, K. V., Siddiqui, A. H., et al. (2022) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.122.000536 · Cited by 16
Santo, B. A., Sarayi, S. M. M. J., McCall, A. D., Monteiro, A., Donnelly, B. M., Siddiqui, A. H., & Tutino, V. M. (2023) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2022-019967 · Cited by 16
Liu, H., Jing, J., Wang, A., Xu, Q., Meng, X., Li, H., Li, Z., & Wang, Y. (2023) · Stroke · doi:10.1161/strokeaha.122.041738 · Cited by 16
Current perspectives on the clinical management of cryptogenic stroke
Yang, D., & Elkind, M. S. V. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2192403 · Cited by 17
Jia, L., Yang, H., Jiao, L., Ma, Y., Xing, Y., Wang, L., Hui, P., Pan, X., Fang, Y., Peng, T., et al. (2023) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2023.03.500 · Cited by 16
Sun, M.-Y., & Bhaskar, S. M. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097981 · Cited by 16
Chen, P., Wang, C.-S., Huang, J., Fu, Y., Liao, N.-C., Hsu, C., & Wu, Y.-H. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1190011 · Cited by 16
Atrial Fibrillation Detection and Load: Knowledge Gaps Related to Stroke Prevention
Smith, E. E., Yaghi, S. R., Sposato, L. A., Fisher, M., Broderick, J. P., Das, A. S., Elkind, M. S. V., Goldstein, L. B., Gurol, M. E., Kamel, H., et al. (2023) · Stroke · doi:10.1161/strokeaha.123.043665 · Cited by 17
Self-citationCargnin, S., Ferrari, F., & Terrazzino, S. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07534-0 · Cited by 16
Heo, J., Lee, H., Lee, I. H., Lim, I. H., Hong, S.-H., Shin, J., Nam, H. S., & Kim, Y. D. (2024) · Scientific Reports · doi:10.1038/s41598-023-51013-3 · Cited by 18
Lee, T.-H., Uchiyama, S., Kusuma, Y., Chiu, H.-C., Navarro, J. C., Tan, K.-S., Pandian, J., Guo, L., Wong, Y., & Venketasubramanian, N. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1346177 · Cited by 15
May, J. E., & Moll, S. (2024) · Blood · doi:10.1182/blood.2023021638 · Cited by 20
Arterial Thromboembolism in Japanese Patients With Cancer
Gon, Y., Morishima, T., Kawano, T., Okazaki, S., Todo, K., Sasaki, T., Mochizuki, H., & Miyashiro, I. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.01.006 · Cited by 16
Gao, X., Liu, D., Yue, K., Zhang, Z., Jiang, X., & Luo, P. (2024) · Biomolecules · doi:10.3390/biom14030378 · Cited by 17
Zeinhom, M. G., Elbassiouny, A. A. I., Mohamed, A. M., & Ahmed, S. R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01080-5 · Cited by 16
Zhang, A., Zhu, Y., Liao, J., Wu, D., Yan, X., Chen, J., He, Q., Song, F., Li, L., Li, Y., et al. (2024) · Neuroepidemiology · doi:10.1159/000539132 · Cited by 16
de Diego-Alonso, C., López, P. B., Blasco-Abadía, J., Buesa-Estéllez, A., Roldán-Pérez, P., Medina‐Rincón, A., López-Royo, M. P., Giner-Nicolás, R., Doménech‐García, V., & Fini, N. A. (2024) · Disability and health journal · doi:10.1016/j.dhjo.2024.101640 · Cited by 18
Lee, P. H., Kim, J., Song, J., Kwon, S. U., Kim, B. J., Lee, J. S., Sun, B. J., Woo, J. S., Ann, S. H., Suh, J., et al. (2024) · Journal of Stroke · doi:10.5853/jos.2023.03265 · Cited by 16
Fernando, F. R., Andrés, M. S., Claudiani, S., Kermani, N. Z., Ceccarelli, G., Innes, A. J., Khan, A., Rosen, S. D., Apperley, J. F., Lyon, A. R., et al. (2024) · Cardio-Oncology · doi:10.1186/s40959-024-00245-x · Cited by 18
The Hidden Heart: Exploring Cardiac Damage Post-Stroke: A Narrative Review
Mitrică, M., Lorusso, L., Badea, A.-A., Sîrbu, C. A., Pleșa, A., Stănescu, A. M. A., Pleşa, C., Sîrbu, O.-M., & Munteanu, A. E. (2024) · Medicina · doi:10.3390/medicina60101699 · Cited by 18
Association between Blood Pressure, Blood Pressure Variability, and Post-Stroke Cognitive Impairment
Lee, K., Chang, A. Y., & Sung, P. (2021) · Biomedicines · doi:10.3390/biomedicines9070773 · Cited by 17
Patomella, A., Farías, L., Eriksson, C., Guidetti, S. G. E., & Asaba, E. (2021) · Healthcare · doi:10.3390/healthcare9080968 · Cited by 19
Kang, X., Jiao, T., Wang, H., Pernow, J., & Wirdefeldt, K. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103824 · Cited by 16
Association between Preexisting Sarcopenia and Stroke in Patients with Type 2 Diabetes Mellitus
Chai, K.-C., Chen, W.-M., Chen, M.-H., Shia, B., & Wu, S. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1846-0 · Cited by 16
Han, L., Hou, Z., Ma, M., Ding, D., Wang, D., & Fang, Q. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1073267 · Cited by 16
Lampert, J., Power, D., Havaldar, S., Govindarajulu, U. S., Kawamura, I., Maan, A., Miller, M. A., Menon, K. M., Koruth, J. S., Whang, W., et al. (2023) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2023.04.006 · Cited by 16
Kim, A., Kamel, H., Bernstein, R. A., Manchanda, M., & Caprio, F. Z. (2022) · Stroke · doi:10.1161/strokeaha.122.037342 · Cited by 16
Self-citationMyocardial infarction, stroke and arterial stenosis: time to reassess a major misunderstanding
Saba, L., & Libby, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01186-3 · Cited by 19
Duloquin, G., Crespy, V., Jakubina, P., Giroud, M., Vergely, C., & Béjot, Y. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.796046 · Cited by 15
Baker, A. D., Schwamm, L. H., Sanborn, D. Y., Furie, K. L., Stretz, C., Grory, B. M., Yaghi, S. R., Kleindorfer, D., Sucharew, H., Mackey, J. S., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.036706 · Cited by 15
Self-citationAnnoni, F., Moro, F., Caruso, E., Zoerle, T., Taccone, F. S., & Zanier, E. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841692 · Cited by 15
Geriatric Nutritional Risk Index and the Prognosis of Patients with Stroke: A Meta-Analysis
Hu, J., Chen, T., Wang, Z., Chen, X., Lin, K., Zhang, G., & Wu, J. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1886-4276 · Cited by 15
Singh, A., Nasir, U., Segal, J., Waheed, T. A., Ameen, M., & Hafeez, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1023562 · Cited by 15
Williams, D. M., Atkinson, M., & Evans, M. (2023) · Stroke · doi:10.1161/strokeaha.122.042109 · Cited by 16
Li, Y., Liu, X., Chen, S., Wang, J., Pan, C., Li, G., & Tang, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14175 · Cited by 15
Ratajczak‐Tretel, B., Lambert, A. T., Al-Ani, R., Arntzen, K., Bakkejord, G. K., Bekkeseth, H. M. O., Bjerkeli, V., Eldøen, G., Gulsvik, A. K., Halvorsen, B. L., et al. (2023) · BMC Neurology · doi:10.1186/s12883-023-03155-0 · Cited by 15
Prevalence and incidence of stroke among people with HIV
Du, M., Wang, Y., Qin, C., Mi, D., Liu, M., & Liu, J. (2023) · AIDS · doi:10.1097/qad.0000000000003632 · Cited by 15
Xie, X., Jing, J., Meng, X., Johnston, S. C., Bath, P. M., Li, Z., Zhao, X., Liu, L., Wang, Y., Xu, Q., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.042233 · Cited by 17
Admission LDL-cholesterol, statin pretreatment and early outcomes in acute ischemic stroke
Kim, J., Lee, J. S., Kim, B. J., Kang, J., Lee, K., Park, J., Kang, K., Lee, S. J., Kim, J. G., Cha, J., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.08.002 · Cited by 15
Tekieli, Ł. M., Kabłak-Ziembicka, A., Dabrowski, W., Dzierwa, K., Moczulski, Z., Urbańczyk‐Zawadzka, M., Mazurek, A., Stefaniak, J., Paluszek, P., Krupiński, M., et al. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02875-1 · Cited by 16
Clinician Response to Pharmacogenetic Clinical Decision Support Alerts
Lemke, L. K., Cicali, E. J., Williams, R., Nguyen, K. A., Cavallari, L. H., & Wiisanen, K. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3051 · Cited by 18
Li, S., Tang, M., Zhang, D., Han, F., Zhou, L., Yao, M., Li, M. L., Cui, L., Zhang, S., Peng, B., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.16057 · Cited by 15
Premorbid sarcopenia and functional outcome after acute stroke: a meta-analysis.
Li, Y., Hong, M., & Shi, H. (2023) · PubMed Central · doi:10.6133/apjcn.202309_32(3).0004 · Cited by 15
Evolving Clinical–Translational Investigations of Cerebroprotection in Ischemic Stroke
Li, Y., Schappell, L. E., Polizu, C., DiPersio, J., Tsirka, S. E., Halterman, M. W., & Nadkarni, N. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216715 · Cited by 14
Seven Strategies to Integrate Equity within Translational Research in Neurology
Lizárraga, K. J., Gyang, T. V., Benson, R. T., Birbeck, G. L., Johnston, K. C., Royal, W., Sacco, R. L., Segal, B. M., Vickrey, B. G., Griggs, R. C., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26873 · Cited by 15
Chan, B., Wong, L. Y. H., Tan, B. Y., Yeo, L. L. L., & Venketasubramanian, N. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11020048 · Cited by 19
Momic, J., Yassin, N., Kim, M. Y., Walser, E., Smith, S. A., Ball, I. M., Moffat, B. S., Parry, N. G., & Vogt, K. (2024) · Injury · doi:10.1016/j.injury.2024.111485 · Cited by 15
Self-citationFreitas, T. E., Costa, A. I., Neves, L., Barros, C., Martins, M., Freitas, P., Noronha, D., Freitas, P., Faria, T., Borges, S., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1408111 · Cited by 15
Fibromuscular Dysplasia: A Focused Review for the Cardiologist
Petropoulos, T., Shah, A., Dueck, A. D., Hawkes, C., Tobe, S. W., Kingston, W. S., & Madan, M. (2024) · CJC Open · doi:10.1016/j.cjco.2024.07.014 · Cited by 15
Shugg, T., Tillman, E. M., Breman, A. M., Hodge, J. C., McDonald, C., Ly, R. C., Rowe, E. J., Osei, W., Smith, T. B., Schwartz, P. H., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3402 · Cited by 15
Ahmed, S. R., Nahas, N. M. E., Khalil, M. F. E., Elbassiouny, A. A. I., Almoataz, M. A., Omar, T. Y., Daabis, A. M. A., Refat, H. M., Ebied, A. A. M. K., Hassan, A. M., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01127-7 · Cited by 15
Symptom clusters and networks analysis in acute-phase stroke patients: a cross-sectional study
Zhou, S., Zhang, Y., He, H., Wang, X., Li, M., Zhang, N., & Song, J. (2025) · Scientific Reports · doi:10.1038/s41598-024-84642-3 · Cited by 15
Cryptogenic stroke. Part 2: paradoxical embolism
Kulesh, A. A., Demin, D. A., Belopasova, A. V., Александрович, М. С., Vinogradov, O. I., Syromyatnikova, L. I., & Ziankou, A. А. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-19-16-33 · Cited by 15
Chen, Y., Mofatteh, M., Nguyen, T. N., Wellington, J., Wei, W., Liang, W., Chen, G., Hu, Z., Ouyang, K., & Yang, S. (2021) · Vascular and Endovascular Surgery · doi:10.1177/15385744211072660 · Cited by 15
Self-citationYaghi, S. R., Ryan, M. P., Gunnarsson, C., Irish, W. D., Rosemas, S. C., Neisen, K. B., Ziegler, P., & Reynolds, M. R. (2022) · Heart Rhythm O2 · doi:10.1016/j.hroo.2022.02.006 · Cited by 15
Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia
Hidayat, R., Nabilah, R. A., Rasyid, A., Harris, S., Harahap, A. R., Herqutanto, H., Louisa, M., Listiyaningsih, E., Rambe, A. S., & Loho, T. (2022) · Acta Medica Academica · doi:10.5644/ama2006-124.367 · Cited by 15
The pharmacological treatment of acute vestibular syndrome
Viola, P., Gioacchini, F. M., Astorina, A., Pisani, D., Scarpa, A., Marcianò, G., Casarella, A., Basile, E., Rania, V., Re, M., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.999112 · Cited by 18
Ultrasound diagnosis of carotid artery stenosis and occlusion
Takekawa, H., Tsukui, D., Kobayashi, S., Suzuki, K., & Hamaguchi, H. (2022) · Journal of Medical Ultrasonics · doi:10.1007/s10396-022-01259-7 · Cited by 15
Gao, P., He, X., Wang, H., Wang, T., Wang, D., Shi, H., Li, T., Zhao, Z., Cai, Y., Wu, W., et al. (2025) · Stroke · doi:10.1161/strokeaha.124.049602 · Cited by 14
Li, Y., Jiang, J., Zhuo, Y., Li, J., Li, Y., Xia, Y., & Yu, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167877 · Cited by 14
Zaman, A., Yassin, M. M., Mehmud, I., Cao, A., Lu, J., Hassan, H., & Kang, Y. (2025) · Methods · doi:10.1016/j.ymeth.2025.04.016 · Cited by 14
PFO Device Closure in Patients >60 Years of Age With Ischemic Stroke
Satpathy, R., Rodés‐Cabau, J., Thaler, D. E., Kent, D. M., Turner, S. J., Potluri, S. P., Kolli, K. K., Borgstrom, N. P., Prillinger, J. B., & Saver, J. L. (2025) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2025.03.034 · Cited by 14
Polygenic Susceptibility to Hypertension and Blood Pressure Control in Stroke Survivors
Acosta, J., Both, C. P., Demarais, Z. S., Conlon, C. J., Leasure, A. C., Torres‐Lopez, V., de Havenon, A., Petersen, N., Gill, T. M., Sansing, L. H., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000206763 · Cited by 14
Chen, Y., Yang, H., Lan, M., Wei, H., & Chen, Y. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1067706 · Cited by 14
Hu, H., Qiu, J., Li, W., Nguyen, T. N., Wang, F., Li, D., Shi, H., Wang, S., Wei, M., & Chen, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1154736 · Cited by 14
Self-citationStroke in Atrial Fibrillation and Other Atrial Dysrhythmias
Ozdemir, H., Sagris, D., Lip, G. Y. H., & Abdul‐Rahim, A. H. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01862-1 · Cited by 16
Hong, K., Bang, O. Y., Park, J., Jung, J.-M., Lee, S. H., Song, T., Nam, H. S., Park, H.-K., Jung, K., Heo, S. H., et al. (2023) · Journal of Stroke · doi:10.5853/jos.2022.02957 · Cited by 17
Wichaiyo, S., Parichatikanond, W., Visansirikul, S., Saengklub, N., & Rattanavipanon, W. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00052 · Cited by 14
Chou, P., Hung, W., Yang, I.-H., Kuo, C.-M., Wu, M., Lin, T.-C., Fong, Y.-O., Juan, C.-H., & Lai, C. (2023) · Microorganisms · doi:10.3390/microorganisms11082016 · Cited by 14
Akyea, R. K., Ntaios, G., Kontopantelis, E., Georgiopoulos, G. A., Soria, D., Asselbergs, F. W., Kai, J., Weng, S. F., & Qureshi, N. (2023) · PLOS Digital Health · doi:10.1371/journal.pdig.0000334 · Cited by 15
Naqvi, I. A., Strobino, K., Li, H., Schmitt, K., Baratt, Y., Ferrara, S. A., Hasni, A., Cato, K., Weiner, M. G., Elkind, M. S. V., et al. (2023) · Applied Clinical Informatics · doi:10.1055/s-0043-1772679 · Cited by 14
Rajesh, K., Spring, K. J., Beran, R. G., & Bhaskar, S. M. M. (2023) · Nephrology · doi:10.1111/nep.14251 · Cited by 14
Doi, S., Yoneyama, K., Yoshida, T., Kawagoe, Y., Nakai, M., Sumita, Y., Ishibashi, Y., Izumo, M., Tanabe, Y., Harada, T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47998-6 · Cited by 14
Systematic Review of Machine Learning Applied to the Secondary Prevention of Ischemic Stroke
Chen, M., Qian, D., Wang, Y., An, J., Meng, K., Xu, S., Liu, S., Sun, M., Li, M., & Pang, C. (2024) · Journal of Medical Systems · doi:10.1007/s10916-023-02020-4 · Cited by 15
Liver Metabolism in Ischemic Stroke
Inderhees, J., & Schwaninger, M. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2023.12.013 · Cited by 14
Zhang, J., Huang, X., Wang, G., Wang, X., Zhang, T., Wang, D., Qi, L., Liang, J., Li, B., Chu, J., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209217 · Cited by 14
Cuccurullo, S. J., Fleming, T. K., Petrosyan, H. A., Hanley, D. F., & Raghavan, P. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1376616 · Cited by 14
Shi, Y., Zhang, Z., Wang, B., Wang, Y., Kong, X., Sun, Y., Li, A., Cui, Y., Zhang, Y., Li, J., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01817-0 · Cited by 14
Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment
Tannu, M., Hess, C. N., Gutierrez, J. A., Lópes, R. D., Swaminathan, R. V., Altin, S. E., & Rao, S. V. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02063-0 · Cited by 15
Self-citationUpdates on Patent Foramen Ovale (PFO) Closure
Voudris, K. V., Poulin, M., & Kavinsky, C. J. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02073-y · Cited by 14
Natriuretic Peptides to Classify Risk of Atrial Fibrillation Detection After Stroke
Cameron, A. C., Arnold, M., Katsas, G., Yang, J., Quinn, T. J., Abdul‐Rahim, A. H., Campbell, R., Docherty, K. F., Marchis, G. M. D., Arnold, M., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209625 · Cited by 14
Ashizawa, R., Honda, H., Take, K., Yoshizawa, K., Kameyama, Y., Yamashita, S., Wakabayashi, T., & Yoshimoto, Y. (2024) · Physiotherapy Research International · doi:10.1002/pri.2110 · Cited by 16
Carroll, J., Manzano, C. L., Tomlinson, E., Sadek, A., Cooper, C., Jones, H. E., Rowsell, L., Knight, J., Mumford, A. D., Palmer, R., et al. (2024) · Health Technology Assessment · doi:10.3310/pwcb4016 · Cited by 16
Zeng, C., Chen, Z., Yang, H., Fan, Y., Fei, L., Chen, X., & Zhang, M. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64373 · Cited by 17
Wang, Y., Liu, C., Chen, Y., Chen, T., Tao, H., Xue, L., & Xu, B. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.876087 · Cited by 14
The use of dual antiplatelet therapy for ischemic cerebrovascular events
Mele, F., Gendarini, C., & Pantoni, L. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06395-z · Cited by 14
Bose, S., Stonko, D. P., Pappas, G. M., Drudi, L. M., Stoner, M. C., & Hicks, C. W. (2022) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2022.09.028 · Cited by 14
Miller, A. E., Collier, Z. K., & Reisman, D. S. (2022) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-022-01091-7 · Cited by 13
Is improved access to magnetic resonance imaging imperative for optimal ischemic stroke care?
Kumar, M., Hu, S., Beyea, S., & Kamal, N. R. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120592 · Cited by 14
Li, Y., Miao, L., Guo, R., He, L., Sun, M., Pan, Y., Lin, L., Ren, J., & Liu, J. (2023) · Journal of Proteomics · doi:10.1016/j.jprot.2023.104850 · Cited by 14
GPT-4 as a Clinical Decision Support Tool in Ischemic Stroke Management: Evaluation Study
Shmilovitch, A. H., Katson, M., Cohen-Shelly, M., Peretz, S., Aran, D., & Shelly, S. (2025) · JMIR AI · doi:10.2196/60391 · Cited by 13
Effect of Intensive Blood Pressure Control on Stroke
Li, J., Lei, L., Li, Y., Zhang, H., Yan, X., Sun, Y. H., He, D., Du, L., Hu, J., Qi, L., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.055 · Cited by 17
Bailey, R. R., & Ipsen, M. (2022) · Disability and health journal · doi:10.1016/j.dhjo.2022.101270 · Cited by 14
Ten Good Reasons to Practice Neuroultrasound in Critical Care Setting
Rynkowski, C. B., & Caldas, J. R. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.799421 · Cited by 13
Metadata
- Authors
- Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., Lennon, O., Meschia, J. F., Nguyen, T. N., Pollak, P. M., Santangeli, P., Sharrief, A. Z., Smith, S. C., Turan, T. N., & Williams, L. S.
- ORCID
- Venue
- Stroke
- Published
- 2021-07
- Volume
- 52
- Issue
- 7
- Pages
- e364-e467
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W3164908038
- Semantic Scholar
- 18bb9d19bdfe54d5d1289c0a74fbcb410e3e1b6d
- Cited by
- 3,237
- References
- 892
- Citations by year
- 2026: 653 · 2025: 670 · 2024: 778 · 2023: 618 · 2022: 432 · 2021: 82
- FWCI
- 72.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-06-28)
- Open access
- bronze
- doi.org
- Locations
- Stroke (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- Congress of Neurological Surgeons
- Topics
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- secondary stroke prevention, stroke recurrence, transient ischemic attack, stroke risk factors
- MeSH terms
- Clinical Decision-Making, American Heart Association, Ischemic Attack, Transient, Humans, United States, Practice Guidelines as Topic, Stroke, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
